5-(2-{2,8-dimethyl-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-5-yl}ethyl)-2-methylpyridine dihydrochloride

• ChemBase ID: 72591
• Molecular Formular: C21H27Cl2N3
• Molecular Mass: 392.36518
• Monoisotopic Mass: 391.15820324
• SMILES: n1(c2c(c3c1ccc(c3)C)CN(CC2)C)CCc1ccc(nc1)C.Cl.Cl
• Canonical SMILES: CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(nc1)C.Cl.Cl
• InChI: InChI=1S/C21H25N3.2ClH/c1-15-4-7-20-18(12-15)19-14-23(3)10-9-21(19)24(20)11-8-17-6-5-16(2)22-13-17;;/h4-7,12-13H,8-11,14H2,1-3H3;2*1H
• InChIKey: GTWLIQOLGOZTLF-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 5-(2-{2,8-dimethyl-1H,2H,3H,4H,5H-pyrido[4,3-b]indol-5-yl}ethyl)-2-methylpyridine dihydrochloride
• IUPAC Traditional name: 5-(2-{2,8-dimethyl-1H,3H,4H-pyrido[4,3-b]indol-5-yl}ethyl)-2-methylpyridine dihydrochloride
• Synonyms: Latrepirdine; Dimebolin; Dimebon

Database IDs

• CAS Number: 97657-92-6
• PubChem SID: 162037516
• PubChem CID: 23729232

CALCULATED PROPERTIES

• H Acceptors: 2
• H Donor: 0
• LogD (pH = 5.5): 0.8634037
• LogD (pH = 7.4): 3.081123
• Log P: 3.4085224
• Molar Refractivity: 100.7248 cm^3
• Polarizability: 39.457382 Å^3
• Polar Surface Area: 21.06 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: Histamine receptors

Product Information

• Salt Data: Hydrochloride

DETAILS

Selleck Chemicals - S1245

Research Area: Neurological Disease
Biological Activity:
Latrepirdine (INN, also known as dimebolin and sold as Dimebon), is an antihistamine drug. Research is continuing in both Russia and western nations into potential applications as a neuroprotective drug to combat Alzheimer’s disease and, possibly, as a nootropic as well. However, a Phase III clinical trial for Alzheimer’s disease treatment failed to show any benefit. [1]Latrepirdine operates through multiple mechanisms of action, blocking the action of neurotoxic beta-amyloid proteins, inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors, exerting a neuroprotective effect by blocking a novel target that involves mitochondrial pores, blocking a number of other receptors including α-adrenergic, 5-HT2C, 5-HT5A, and 5-HT6. [1]

REFERENCES

• http://en.wikipedia.org/wiki/Latrepirdine